A 72-year-old woman with hypertension and CKD stage 3a (eGFR 52 mL/min/1.73m²) is started on lisinopril 10 mg daily. Repeat serum creatinine measured 2 weeks later is 2.1 mg/dL (baseline 1.6 mg/dL). Serum potassium is 5.8 mEq/L (normal 3.5–5.0). What is the most appropriate next step?

Explanation

## Clinical Context This patient has experienced an expected acute rise in serum creatinine (~31% increase) and mild hyperkalemia after ACE inhibitor initiation. These are **predictable, usually transient changes** that reflect the drug's renoprotective mechanism — NOT an indication for discontinuation. ## Key Point: **A transient rise in serum creatinine (10–20%, sometimes up to 30%) within 2–4 weeks of ACE-I/ARB initiation is EXPECTED and does NOT warrant drug discontinuation.** This reflects loss of efferent arteriolar vasoconstriction and is a sign that the drug is working. ## High-Yield: **Mild hyperkalemia (K⁺ 5.5–6.0 mEq/L) in the setting of ACE-I initiation is common and often resolves with dietary restriction.** Urgent intervention is needed only if K⁺ > 6.5 mEq/L or ECG changes are present. ## Clinical Pearl: **The "rule of thirds" for ACE-I/ARB response:** - 1/3 of patients: creatinine stable or improves - 1/3 of patients: transient rise (10–30%), then stabilizes - 1/3 of patients: progressive decline (indicates non-ACE-I-responsive disease; consider renal artery stenosis or other pathology) ## Management Decision Tree ```mermaid flowchart TD A[ACE-I started; Cr ↑ 10-30%, K+ 5.5-6.0]:::outcome --> B{Magnitude of Cr rise & K+ level?}:::decision B -->|Cr rise < 30% AND K+ < 6.5 AND no ECG changes| C[CONTINUE ACE-I]:::action B -->|Cr rise > 30% OR K+ > 6.5 OR ECG changes| D[Discontinue ACE-I; investigate]:::urgent C --> E[Dietary K+ restriction]:::action C --> F[Recheck labs in 4 weeks]:::action D --> G[Rule out RAS, acute GN, other causes]:::action F --> H{Cr & K+ stable or improving?}:::decision H -->|Yes| I[Continue long-term; recheck 3-monthly]:::action H -->|No| J[Reassess; consider alternative agent]:::action ``` ## Hyperkalemia Management Thresholds | K⁺ Level | Clinical Action | |----------|----------------| | 5.0–5.5 | Dietary restriction; recheck in 1–2 weeks | | 5.5–6.0 | Dietary restriction + consider low-dose diuretic; recheck in 2–4 weeks | | 6.0–6.5 | Dietary restriction + diuretic + consider dose reduction of ACE-I | | > 6.5 | Discontinue ACE-I; consider acute intervention (calcium gluconate, insulin + glucose, sodium polystyrene sulfonate) | ## Tip: **Do NOT confuse transient, expected changes with drug toxicity.** The goal is to allow time (4–6 weeks) for stabilization before deciding to discontinue. [cite:Harrison 21e Ch 297; Robbins 10e Ch 19]